TrialInternational journal of hematology2015

Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy.

Yoshitaka Miyakawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.